• Protara Therapeutics completed enrollment of 24 patients in the Phase 2b dose-confirmation portion of its registrational THRIVE-3 trial of IV Choline Chloride.
• The treatment targets choline deficiency in patients with intestinal failure who depend on parenteral support.
• Interim Phase 2b results are expected in the fourth quarter of 2026; the study will guide dose selection.
• The randomized, placebo-controlled Phase 3 portion will enroll approximately 100 patients to evaluate improvement in plasma choline levels and safety.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protara Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610150800PRIMZONEFULLFEED9846094) on October 15, 2026, and is solely responsible for the information contained therein.